Editas Medicine Inc., a pioneering gene editing company, has announced a significant milestone in its collaboration with Bristol Myers Squibb. The company has successfully secured its first IND/CTA acceptance for the CD19 HD Allo CAR T program, marking a crucial step forward in their joint efforts. This acceptance has also triggered a milestone payment to Editas, highlighting the progress and potential of their collaborative program. This development is part of Editas' broader strategy to advance transformative medicines for serious diseases and underscores their ongoing commitment to innovation in gene editing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.